NFKB1 and Insulin resistance: Pharmacological inhibition or genetic deletion of components of the NF‐κB pathway (i) prevents the development of HFD‐induced insulin resistance (Chiazza et al., 2015) (Benzler et al., 2015) and (ii) slows the progression of microvascular disease.